Adecatumumab MT 201; Anti-Human EPCAM Recombinant Antibody|cas:503605-66-1|西域试剂

Adecatumumab MT 201; Anti-Human EPCAM Recombinant Antibody,95.00%

产品编号：Bellancom-P99278| CAS NO：503605-66-1

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-P99278	￥3500.00	杭州北京（现货）
Bellancom-P99278	￥9700.00	杭州北京（现货）
Bellancom-P99278	￥15000.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Adecatumumab MT 201; Anti-Human EPCAM Recombinant Antibody

产品介绍

Adecatumumab (Anti-Human EPCAM Recombinant Antibody; MT201) 是 IgG1 同型的全人单克隆抗体，靶向人 EpCAM。Adecatumumab 在几乎所有腺癌中都有表达，其活性与 K-Ras 状态无关。

生物活性

Adecatumumab (Anti-Human EPCAM Recombinant Antibody; MT201) is a full human monoclonal antibody of the IgG1 isotype, targeting human EpCAM. Adecatumumab is expressed in almost all adenocarcinomas, and its activity is not dependent of K-Ras status.

体外研究

Adecatumumab (4 μM; 18 h) shows diverse kinetic binding activities among human Adecatumumab and murine Adecatumumab in B16/EpCAM 3E3 cells.
Adecatumumab (0.1 ng/mL-0.1 mg/mL; 4 h) shows a dose-dependent Antibodies depend on cell-mediated cytotoxicity (ADCC) activity in natural killing (NK) cells.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

Adecatumumab (300 μg/mouse; i.v. bolus injection; 3 times per week) inhibits tumor growth in B16/EpCAM xenograft tumor model in mice, both of human adecatumumab and mu-adecatumumab.
Both human adecatumumab and mu-adecatumumab (300 μg/mouse; i.v. bolus injection; single dose) exhibit a bi-exponential curve progression of serum concentration with an early distribution phase between 0 and 10 h and a terminal elimination phase.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female immunocompetent C57BL/6 mice (6-10 weeks old) with B16/EpCAM (i.v.)
Dosage:	250 μg/mouse and 600 μg/mouse for human Adecatumumab; 125 μg/mouse and 300 μg/mouse for murine Adecatumumab
Administration:	250 μg/mouse and 600 μg/mouse for human Adecatumumab; 125 μg/mouse and 300 μg/mouse for murine Adecatumumab
Result:	Both of them exhibited anti-tumor activity against B16/EpCAM cells in mice. Although human adecatumumab inhibited the size of tumor colonies mice, the number of colonies was only slightly reduced after treatment without significant difference. In contrast, mu-adecatumumab induced a highly significant reduction in the number of lung tumor colonies by >85%, and the few remaining tumor colonies were of very small size.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female immunocompetent C57BL/6 mice (6-10 weeks old) with B16/EpCAM (i.v.)
Dosage:	250 μg/mouse and 600 μg/mouse for human Adecatumumab; 125 μg/mouse and 300 μg/mouse for murine Adecatumumab
Administration:	250 μg/mouse and 600 μg/mouse for human Adecatumumab; 125 μg/mouse and 300 μg/mouse for murine Adecatumumab
Result:	Both of them exhibited anti-tumor activity against B16/EpCAM cells in mice. Although human adecatumumab inhibited the size of tumor colonies mice, the number of colonies was only slightly reduced after treatment without significant difference. In contrast, mu-adecatumumab induced a highly significant reduction in the number of lung tumor colonies by >85%, and the few remaining tumor colonies were of very small size.